Market Size of Iran Diabetes Care Drugs Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Market Size (2024) | USD 331.92 Million |
Market Size (2029) | USD 401.90 Million |
CAGR (2024 - 2029) | 3.90 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Iran Diabetes Care Drugs Market Analysis
The Iran Diabetes Care Drugs Market size is estimated at USD 331.92 million in 2024, and is expected to reach USD 401.90 million by 2029, growing at a CAGR of 3.9% during the forecast period (2024-2029).
According to the World Health Organization's 2022 report, the prevalence of diabetes in Iran stands at 10.3%, with rates of 9.6% for men and 11.1% for women. In Yazd province, the prevalence of diabetes is notably higher at 16.3%. This disease is a result of a combination of genetic and environmental factors.
The rapid and significant lifestyle changes observed in many countries have led to an increase in obesity and other risk factors for non-communicable diseases. Common risk factors for diabetes include being overweight, obesity, low physical activity, high fat consumption, low fiber diet, race, family history, age, low birth weight, smoking, and high blood pressure.
Diabetes mellitus poses a significant healthcare challenge in Yazd province due to its prevalence, costs, and impact on individuals' lives, although it can be managed and prevented. Lifestyle-related factors play a crucial role in the early development of type 2 diabetes. Identifying these risk factors, understanding their individual contributions, and implementing interventions based on them are essential steps in diabetes management and prevention of complications.
Overall, the rise in the use of diabetes medications in iran is a positive development that reflects the growing awareness and understanding of diabetes as a chronic disease that requires ongoing management and treatment. With continued advancements in diabetes drug treatments and increased access to healthcare services, the diabetic population in iran can look forward to better outcomes and improved quality of life in the years to come.